Literature DB >> 20547009

Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy.

Serdar Soyuer1, Isin Soyuer, Dilek Unal, Kadir Ucar, Oguz Galip Yildiz, Okan Orhan.   

Abstract

The tetraspanin transmembrane protein CD9 plays an important role in inhibiting cell motility in numerous neoplastic cell lines, including lung, gastric, pancreatic, and bladder carcinomas. The prognostic importance of CD9 in the survival of gastric carcinoma patients has not been examined to date, and in the present study, we attempted to define its prognostic value. The study included 49 (35 men and 14 women) patients with locally advanced (stages II-IV) gastric cancer. The median age was 55 years (range, 22-73 years). Surgery was the initial treatment for all patients, followed by adjuvant chemoradiotherapy. Tissue sections were evaluated immunohistochemically with a monoclonal anti-CD9 antibody. Of the 49 patients with gastric adenocarcinoma, 11 (22.4%) were CD9-positive, and 38 (77.6%) were CD9-negative. A significant prognostic value in disease-free survival and overall survival was observed in T classification and CD9 positivity. In conclusion, CD9 expression in gastric cancer appears to be associated with poor prognosis. Copyright 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547009     DOI: 10.1016/j.prp.2010.04.004

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  13 in total

Review 1.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

Review 2.  Tetraspanin proteins promote multiple cancer stages.

Authors:  Martin E Hemler
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

Review 3.  Novel CD9-targeted therapies in gastric cancer.

Authors:  Yoko Murayama; Kenji Oritani; Shusaku Tsutsui
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

Review 4.  Proteome-based biomarkers in pancreatic cancer.

Authors:  Chen Sun; Ann H Rosendahl; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2011-11-28       Impact factor: 5.742

Review 5.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

6.  Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.

Authors:  Kelly Pedrozo Ferreira; Bruna Cristine de Almeida; Laura Gonzalez Dos Anjos; Glauco Baiocchi; Fernando Augusto Soares; Rafael Malagoli Rocha; Edmund Chada Baracat; Andrey Senos Dobroff; Katia Candido Carvalho
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

7.  Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via upregulation of matrix metalloproteinase-9.

Authors:  Michael J Herr; Jayaprakash Kotha; Nikolaus Hagedorn; Blake Smith; Lisa K Jennings
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

8.  Expression and clinicopathological significance of CD9 in gastrointestinal stromal tumor.

Authors:  Hongxin Yang; Chaoyong Shen; Bo Zhang; Haining Chen; Zhixin Chen; Jiaping Chen
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

9.  Prognostic value of NF-κB, CD9, and VEGF in gastrointestinal stromal tumors.

Authors:  Arzu Tasdemir; Isin Soyuer; Dilek Unal; Tarik Artis
Journal:  Contemp Oncol (Pozn)       Date:  2013-12-19

10.  Requirement for a standardised definition of advanced gastric cancer.

Authors:  Angelo DE Sol; Stefano Trastulli; Veronica Grassi; Alessia Corsi; Ivan Barillaro; Andrea Boccolini; Micol Sole DI Patrizi; Giorgio DI Rocco; Alberto Santoro; Roberto Cirocchi; Carlo Boselli; Adriano Redler; Giuseppe Noya; Seong-Ho Kong
Journal:  Oncol Lett       Date:  2013-11-11       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.